Dr. Clay Siegall is the co-founder and CEO of a biotech firm that operates out of Seattle, Washington. Seattle Genetics was founded in 1998 and rapidly went from a small startup with a skeleton crew of staff to become a major player in the cancer research field. He got the idea for Seattle Genetics after watching a family member diagnosed with cancer almost die from anemia. The anemia was a result of the chemotherapy drugs they were on to fight their cancer. Dr. Siegall believes there has to be a better way to fight cancer than the old standbys of chemo, surgery, or amputation.
Seattle Genetics markets its own and the first FDA-approved antibody drug conjugate to its medical partners, but it has other revenues to help cover the cost of developing new cancer-fighting drugs. Dr. Siegall believes in hard work and having a dedication to your craft to make it succeed. Seattle Genetics gets a lot of its new customers from negotiations, meetings, and wining and dining them.
Dr. Clay Siegall has a B.S. in Zoology from The University of Maryland as well as a Ph.D. in genetics from George Washington University. Dr. Siegall has worked with the National Cancer Institute from 1988 to 1991. Before he founded Seattle Genetics, he worked with Bristol-Myers Squibb Pharmaceutical Research Institute from 1991 to 1997. To date, Dr. Clay Siegall has written and published over 70 publications and currently holds 15 patents. He is dedicated to his company and furthering their research into new, and better cancer treatment drugs.
Seattle Genetics and Dr. Clay Siegall have both come a long way since its founding almost 20 years ago, and with the way Seattle Genetics is expanding and breaking new ground, it doesn’t show any sign of slowing down. This is excellent news for anyone who is diagnosed with cancer or has a friend or loved one with the diagnosis. Dr. Clay Siegall will be around for years to come, and the world will be better for it.